jyb1904
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 7, 2022 (NCT05449535)
Timeline
Indications
Mechanism of action
- Immunoglobulin epsilon Fc receptorANTAGONIST
FCER2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07220811 | Phase 2 | Oct 31, 2025 | RAPT Therepeutics, Inc. |
| NCT06509334 | Phase 2 | Jul 15, 2024 | Jemincare |
| NCT06438757 | Phase 2 | Jun 19, 2024 | Jemincare, Jiao Tong University |
| NCT05449535 | Phase 1 | May 7, 2022 | Hangzhou Hospital of Traditional Chinese Medicine, Jemincare |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jemincare | For profit | 3 | 3 | 2 | 2022 |
| Hangzhou Hospital of Traditional Chinese Medicine | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| RAPT Therepeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1